Searched for
LUPIN IN US
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Suryoday Small Finance Bank reports Q4 profit at Rs 49 croreSuryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- El Nino impact: Which stocks will burn & which will fire up as market braces for heat waveIndia faces a strong El Niño, threatening below-normal rainfall and impacting agriculture. While rural-linked sectors like two-wheelers and...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Lupin launches generic anti-diabetic tablets in USPharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Lupin gets tentative nod from USFDA for generic Sugammadex injectionLupin Ltd, a prominent name in the pharmaceutical world, revealed on Tuesday that it has gained tentative approval from the US health autho...
- Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mnLupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FD...
- Fundamental Radar: Sales of this single drug can take Lupin’s US revenue to $1 billion in FY-26Lupin's focus on the US portfolio is to increase dollar sales to above $200 million from the earlier range of $170-190 million. Lupin recen...
- Lupin's US arm takes over Symbiomix TherapeuticsLupin had entered into an arrangement to acquire the company earlier this year.
- Lupin launches generic oral contraceptive tablets in USThe USFDA had earlier given approval to market a generic version of Janssen Pharmaceuticals, Inc.'s Ortho Tri-Cyclen tablets in the same st...
- Lupin buys US generics firm Gavis for Rs 5606 croreThe deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said.
- Lupin scouts for acquisitions in USCompany continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and...
- Lupin gains on FDA approval for oral contraceptiveShares of Lupin gained momentum in weak market after it received US FDA approval for oral contraceptive tablets.
- Lupin gets US FDA nod for anti-depressantPharma major Lupin on Tuesday said it has received final approval from the US health regulator for its anti-depression drug Imipramine Pamo...
- Lupin buys US rights of anti-cholesterol drug Antara for $39 mnLupin has bought the US marketing rights and inventory for cholesterol-lowering drug Antara from the bankrupt Oscient Pharma for $39 millio...
Load More
